Log in to your Inderes Free account to see all free content on this page.

Amniotics

Less than 1K followers

Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC). The company is listed at Nasdaq First North Growth Market in Stockholm.

All

Research

Press releases

ShowingAll content types

Regulatory press release9/23/2024, 11:30 AM

The Swedish Companies Registration Office has authorised the implementation of the merger plan between Magle group and Amniotics

Press release8/20/2024, 11:27 AM

Redeye: Amniotics H1 2024 - Merger with Magle

Regulatory press release8/6/2024, 8:45 AM

Amniotics receives conditional approval to delist from Nasdaq First North Growth Market

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release8/6/2024, 6:45 AM

Amniotics applies for delisting from Nasdaq First North Growth Market conditional upon completion of the merger with Magle Group

Regulatory press release7/1/2024, 3:30 PM

Amniotics publishes merger document regarding the merger with Magle Group

Regulatory press release5/30/2024, 6:05 PM

Statement from the Board of Directors of Amniotics regarding the merger with Magle Group

Regulatory press release5/30/2024, 6:00 PM

Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering

Regulatory press release5/21/2024, 7:50 PM

Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement

Regulatory press release3/22/2024, 6:40 AM

Statement from the Board of Directors of Amniotics regarding the public offer from Magle Chemoswed

Regulatory press release3/21/2024, 5:00 PM

Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement

Regulatory press release3/11/2024, 3:00 PM

Amniotics announces the outcome of the exercise of warrants series TO 3

Regulatory press release2/26/2024, 7:30 AM

The exercise period for warrants series TO 3 in Amniotics begins today

Press release2/26/2024, 6:57 AM

Redeye: Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding

Regulatory press release2/22/2024, 2:05 PM

Amniotics AB (publ) Report for the fourth quarter 2023.

Press release12/21/2023, 1:16 PM

Information about the Annual General Meeting and appointed Nomination Committee of Amniotics

Regulatory press release12/14/2023, 10:20 AM

Amniotics receives orphan designation for PulmoStem® from the European Commission for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Press release11/28/2023, 7:30 AM

Redeye: Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study

Regulatory press release11/27/2023, 7:00 AM

Amniotics AB (publ) Report for the third Quarter 2023

Press release11/23/2023, 11:00 AM

Renewed GMP certification

Regulatory press release11/20/2023, 2:40 PM

Amniotics receives positive opinion on orphan designation for PulmoStem® from the European Medicines Agency for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.